MultiCell Technologies Inc. Signs Key Supply Agreement With Lundbeck Pharmaceuticals Italy S.p.A.

09 Apr 2007

·www.biospace.com

Collaborate

SAN DIEGO, CA -- (MARKET WIRE) -- April 09, 2007 -- MultiCell Technologies, Inc. (OTCBB: MCET) has entered into a long-term agreement with Lundbeck Pharmaceuticals Italy S.p.A. for the supply of one of the active components of MCT-125, MultiCell's Phase IIb drug for the treatment of chronic fatigue in patients with multiple sclerosis (MS).

Organizations

Lundbeck Pharmaceuticals Italy SpAMultiCell Technologies, Inc.

H. Lundbeck A/S

Indications

Multiple Sclerosis

Targets

Drugs

L-phenylalanine/Lofepramine Hydrochloride

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.